These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24327718)

  • 1. Targeting resistance in lung cancer.
    Cancer Discov; 2013 Dec; 3(12):OF9. PubMed ID: 24327718
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted therapy in lung cancer: survival, quality of life improved for some patients.
    Printz C
    Cancer; 2014 Sep; 120(17):2625-6. PubMed ID: 25142921
    [No Abstract]   [Full Text] [Related]  

  • 3. Does the addition of vascular endothelial growth factor inhibitors to epidermal growth factor receptor-tyrosine kinase inhibitor overcome T790M acquired resistance?
    Hata A; Kaji R; Fujita S; Katakami N
    J Thorac Oncol; 2011 Feb; 6(2):404. PubMed ID: 21252723
    [No Abstract]   [Full Text] [Related]  

  • 4. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.
    Ara├║jo A; Ribeiro R; Azevedo I; Coelho A; Soares M; Sousa B; Pinto D; Lopes C; Medeiros R; Scagliotti GV
    Oncologist; 2007 Feb; 12(2):201-10. PubMed ID: 17296816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.
    Oxnard GR
    Arch Pathol Lab Med; 2012 Oct; 136(10):1205-9. PubMed ID: 23020725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
    Kotsakis A; Georgoulias V
    Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
    Girard N
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
    Shih JY; Gow CH; Yang PC
    N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
    [No Abstract]   [Full Text] [Related]  

  • 10. Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib.
    Schwab R; Pinter F; Moldavy J; Papay J; Strausz J; Kopper L; Keri G; Pap A; Petak I; Oreskovich K; Mangel L
    J Clin Oncol; 2005 Oct; 23(30):7736-8. PubMed ID: 16234532
    [No Abstract]   [Full Text] [Related]  

  • 11. [Biological therapy in non-small-cell lung cancer (NSCLC)].
    Souquet PJ
    Rev Pneumol Clin; 2004 Nov; 60(5 Pt 3):4S53-4S56. PubMed ID: 15687996
    [No Abstract]   [Full Text] [Related]  

  • 12. Gefitinib. Still no convincing results in non-small cell lung cancer.
    Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
    [No Abstract]   [Full Text] [Related]  

  • 13. Medicine. Why a new cancer drug works well, in some patients.
    Marx J
    Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
    [No Abstract]   [Full Text] [Related]  

  • 14. [Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
    Zhou CC; Deng XF
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):138-40. PubMed ID: 17445479
    [No Abstract]   [Full Text] [Related]  

  • 15. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
    [No Abstract]   [Full Text] [Related]  

  • 16. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
    [No Abstract]   [Full Text] [Related]  

  • 17. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.
    Heuckmann JM; Rauh D; Thomas RK
    J Clin Oncol; 2012 Sep; 30(27):3417-20. PubMed ID: 22915655
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
    Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ
    Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chasing mutations in the epidermal growth factor in lung cancer.
    Dowell JE; Minna JD
    N Engl J Med; 2005 Feb; 352(8):830-2. PubMed ID: 15728818
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.